Acute management of croup in the emergency department

Oliva Ortiz-Alvarez MD; Canadian Paediatric Society, Acute Care Committee, Ottawa, Ontario

Correspondence: Canadian Paediatric Society, 100-2305 St. Laurent Blvd., Ottawa, Ontario K1G 4J8
e-mail: info@cps.ca website: www.cps.ca.

Abstract
Croup is one of the most common causes of upper airway obstruction in young children. It is characterized by sudden onset of barking cough, hoarse voice, inspiratory stridor and respiratory distress caused by upper airway inflammation secondary to a viral infection. Published guidelines for the diagnosis and treatment of croup advise using steroids as the mainstay treatment for all children who present to emergency department (ED) with croup symptoms. Dexamethasone, given orally as a single dose at 0.6 mg/kg, is highly efficacious in treating croup symptoms. Despite the evidence supporting the use of steroids as the cornerstone of croup treatment, there is significant practice variation among physicians treating croup in the ED. This practice point discusses evidence-based management of typical croup in the ED.

Keywords: Corticosteroids; Croup; Dexamethasone; Epinephrine; Heliox

BACKGROUND AND EPIDEMIOLOGY
Most children with croup have mild and short-lived symptoms, with <1% of cases experiencing severe symptoms (1,2). However, croup accounts for significant rates of ED visits and hospitalizations in Canada, with one population-based study in Alberta reporting that 3.2% to 5.1% of all ED visits in children <2 years of age were related to croup (3). Less than 6% of children presenting to ED with croup symptoms require hospitalization and when they are admitted, it is usually for a short stay (3). Endotracheal intubation is rare (at 0.4% to 1.4% of hospitalized cases) and death is exceptionally rare (at 0.5% of intubated cases) (4). There is considerable variation in clinical practice for croup. In small Canadian centres, children with croup are less likely to receive steroids than in larger centres, while the use of antibiotics and beta-agonists (which are rarely indicated in the care of children with croup) is more frequent than in larger centres (5,6).

ETIOLOGY AND PATHOPHYSIOLOGY
Croup is caused by viral infections of the respiratory tract and most commonly by parainfluenza types 1 and 3 viruses. Other implicated viruses are influenza A and B, adenovirus, respiratory syncytial virus and metapneumovirus (7). These infections cause generalized airway inflammation and edema of the upper airway mucosa. The subglottic region becomes narrowed, causing upper airway obstruction and the symptoms typically associated with croup.

CLINICAL PRESENTATION
Classical croup symptoms have a rapid onset and include barking cough, inspiratory stridor, hoarseness and respiratory distress. Nonspecific symptoms of an upper respiratory illness usually precede the typical croup symptoms, which often worsen at night. Typical croup usually affects children between 6 months and 3 years of age. Symptoms are short-lived, usually lasting 3 to 7 days. In 60% of patients, the barking cough disappears after 48 hours (1). In <5% of cases, symptoms may last longer than five nights and <5% of children experience more than one episode. In Canada, croup season peaks over the fall and winter (3,8,9).

DIFFERENTIAL DIAGNOSIS
Children who present with croup at <6 months of age or whose symptoms are recurrent, prolonged or unusually severe require further assessment to rule out congenital or acquired airway narrowing (1). Prolonged duration of croup symptoms associated with fever may be seen with secondary bacterial infection (1). Less than 1% of children with croup have severe or life-threatening symptoms (1,2), but there are several other life-threatening conditions that may present with stridor. Toxic appearance, drooling and dysphagia are important red flags suggestive of more serious conditions (Table 1).

TREATMENT
The severity of the child’s respiratory distress on presentation to the ED should guide management (Table 2). Clinical scores used in research studies have not been shown to improve clinical care (10,11). Most clinicians characterize respiratory distress as mild, moderate, severe or impending respiratory failure. Using this classification, an algorithm for the outpatient management of croup in children was developed through expert consensus (12). Children presenting with severe distress or impending respiratory failure should be referred to paediatric intensive care or to anaesthesia for advanced care when clinical response to initial treatment is poor or not sustained.

Overall, the recommended treatment for croup involves the following measures (Figure 1).

General care
Children should be made comfortable and health care providers must take special care not to frighten them during assessment and treatment. There is
**Table 1. Differential diagnosis**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial tracheitis</td>
<td>High fever, toxic appearance and poor response to nebulized epinephrine</td>
</tr>
<tr>
<td>Retropharyngeal, parapharyngeal, peritonsillar abscesses</td>
<td>High fever, neck pain, sore throat and dysphagia followed by torticollis, drooling, respiratory distress and stridor</td>
</tr>
<tr>
<td>Epiglottitis</td>
<td>Absence of barking cough, sudden onset of high fever, dysphagia, drooling, toxic appearance, anxious appearance and sitting forward in the 'sniffing' position</td>
</tr>
<tr>
<td>Aspiration or ingestion of a foreign body</td>
<td>Croupy cough, choking episode, wheezing, hoarseness, biphasic stridor, dyspnea and decreased air entry</td>
</tr>
<tr>
<td>Acute allergic reaction (anaphylaxis or angioneurotic edema)</td>
<td>Rapid onset of dysphagia, wheezing, stridor and possible cutaneous allergic signs, such as urticarial rash</td>
</tr>
</tbody>
</table>

Adapted from Bjornson and Johnson (9)

**Table 2. Croup severity**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Impending respiratory failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barky cough</td>
<td>Occasional</td>
<td>Frequent</td>
<td>Frequent</td>
<td>Often not prominent due fatigue</td>
</tr>
<tr>
<td>Stridor</td>
<td>None or minimal at rest</td>
<td>Easily audible at rest</td>
<td>Prominent inspiratory and occasionally expiratory</td>
<td>Audible at rest, but may be quiet or hard to hear</td>
</tr>
<tr>
<td>In-drawing suprasternal and/or intercostal</td>
<td>None to mild</td>
<td>Visible at rest</td>
<td>Marked or severe</td>
<td>May not be marked</td>
</tr>
<tr>
<td>Distress, agitation or lethargy (CNS hypoxia)</td>
<td>None</td>
<td>None to limited</td>
<td>Substantial lethargy may be present</td>
<td>Lethargy or decreased level of consciousness</td>
</tr>
<tr>
<td>Cyanosis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Dusky or cyanotic without supplemental oxygen</td>
</tr>
</tbody>
</table>

CNS Central nervous system. Modified from Bjornson and Johnson (1).

There is no evidence to support the treatment of croup with the use of humidified air (13). Mist tents separate children from their caregivers, can disperse fungus and therefore are not recommended (13). The use of antipyretics is beneficial for reducing fever and discomfort.

**Corticosteroids**

The clinical benefit of corticosteroids in croup is well established (2,14–16) and should be considered for treating all children presenting with croup and symptoms ranging from mild to severe. Improvement generally begins within 2 to 3 hours after a single oral dose of dexamethasone and persists for 24 to 48 hours (2,15,16). One recent Cochrane review analyzed results from 38 randomized controlled trials (n=4299) associating corticosteroids with clinical improvement as measured by Westley croup scores at 6, 12 and 24 hours (14).

Dexamethasone was the corticosteroid tested in most (31/38) of these clinical trials (1). The dexamethasone dose used in most clinical trials is 0.6 mg/kg/weight (23).

When the child with croup has persistent vomiting or significant respiratory distress, administering corticosteroids by the intramuscular route may be indicated (1). The dexamethasone dose used in most clinical trials is 0.6 mg/kg/dose (14). It is unclear from studies using doses of 0.15 mg/kg to 0.3 mg/kg whether these smaller doses are equally effective (18). One meta-analysis of six studies suggested that a higher dose could be more beneficial in children with severe disease (15).

Overall, children treated with corticosteroids have fewer return visits or admissions to the hospital. Fully one-half of children with mild croup treated with corticosteroids are unlikely to need further medical care for ongoing symptoms. Their sleep is improved and their parents report less stress (2). In children with moderate to severe croup treated with corticosteroids, there was a reported average reduction of 12 hours in length of stay in the ED or hospital. There was a 10% reduction in the need for treatment with nebulized epinephrine and a 50% reduction in both the number of return visits and in hospitalization rates (14). There have been no adverse events associated with a single dose of corticosteroids for treatment of croup.

**Epinephrine**

Nebulized epinephrine is recommended for moderate to severe croup. Reports of administering epinephrine in children with severe croup have demonstrated a lower number of cases requiring intubation or tracheotomy (19). When compared with a placebo, nebulized epinephrine improved signs of respiratory distress within 10 to 30 minutes of initiating treatment. Clinical effect is sustained for at least 1 hour, but disappears after 2 hours (19). The first prospective trial assessing safe discharge after treating paediatric outpatients with a combination of dexamethasone and nebulized epinephrine, and including observation for 2 to 4 hours, supported the safety of this measure (20). There were no adverse outcomes. These results, along with data from two retrospective cohort studies, clearly support the safe discharge of children, providing that symptoms of croup do not recur 2 to 4 hours after treatment (1,21,22).

Traditionally, racemic epinephrine has been used to treat children with croup. Racemic epinephrine is not readily available in Canada. However, one randomized controlled trial demonstrated that nebulized 1:1000 L-epinephrine is safe and equally effective. Equivalent doses of either 0.5 mL racemic epinephrine or 5 mL of 1:1000 L-epinephrine are equally effective. These standard doses can be used in all patients irrespective of their age and weight (23).
Heliox
A heliox or helium-oxygen mixture can reduce respiratory distress in children with severe croup. A possible mechanism of action is that the lower density of helium gas decreases airflow turbulence in a narrowed airway. Heliox is occasionally used in severe cases to avoid intubation. Heliox has not been shown to improve croup symptoms when compared with standard treatments and therefore is not routinely recommended (24).

Other therapies
The use of antibiotics and short-acting beta-2-agonist bronchodilators in children with typical croup are rarely indicated because of the low incidence of bacterial infection (<1:1000 cases of croup) as well as for physiological reasons. An otorhinolaryngology (ORL) consultation for airway evaluation is indicated when croup symptoms are persistently severe despite treatment. Outpatient referral to ORL is recommended for children with multiple...
croup episodes and for those who present outside the usual age group for typical croup (Figure 1).

Acknowledgements
This practice point has been reviewed by the Community Paediatrics and Infectious Diseases and Immunization Committees of the Canadian Paediatric Society, as well as by the CPS Paediatric Emergency Section Executive.

References
18. Geelhoed GC, Macdonald WB. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol 1995;20(6):362–8.